

**CY 2024 Payment Allowances and Effective Dates for COVID-19 Vaccines**

<b>CPT Code or HCPCS Code</b>	<b>CPT or HCPCS Short Descriptor</b>	<b>Labeler Name</b>	<b>Vaccine/Procedure Name</b>	<b>National Payment Allowance Effective for Claims with DOS on or after 03/15/2021</b>	<b>Effective Dates for Medicare Payment</b>
90480	ADMN SARSCOV2 VACC 1 DOSE	N/A	N/A	\$40.000 <sup>[2]</sup>	09/11/2023 - TBD
M0201	COVID-19 vaccine home admin	Home vaccine admin	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	\$35.50 <sup>[2]</sup>	06/08/2021 - TBD
91304	SARSCOV2 VAC 5MCG/0.5ML IM	Novavax	Novavax Covid-19 Vaccine, Adjuvanted (Aged 12 years and older) 2023-2024 Formula	\$ 148.200	07/13/2022 – 08/29/2024
91318	SARSCOV2 VAC 3MCG TRS-SUC	Pfizer- BioNTech	Pfizer-BioNTech COVID-19 Vaccine 2023-2024 Formula (Yellow Cap)	\$65.550	09/11/2023 - 8/21/2024
91319	SARSCV2 VAC 10MCG TRS-SUC IM	Pfizer- BioNTech	Pfizer-BioNTech COVID-19 Vaccine 2023-2024 Formula (Blue Cap)	\$87.780	09/11/2023 - 8/21/2024
91320	SARSCV2 VAC 30MCG TRS-SUC IM	Pfizer- BioNTech	COMIRNATY (COVID-19 Vaccine, mRNA) 2023-2024 Formula	\$131.100	09/11/2023 – 8/21/2024
91321	SARSCOV2 VAC 25 MCG/.25ML IM	Moderna	Moderna COVID-19 Vaccine 2023-2024 Formula	\$145.920	09/11/2023 – 8/21/2024
91322	SARSCOV2 VAC 50 MCG/0.5ML IM	Moderna	SPIKEVAX 2023-2024 Formula	\$145.920	09/11/2023 – 8/21/2024

<sup>[1]</sup> Since we anticipate that providers, initially, won't incur a cost for the product, CMS will update the payment allowance at a later date. Providers shouldn't bill for the product if they got it for free.

<sup>[2]</sup> We'll also geographically adjust these rates for many providers. We've included files with the geographically adjusted payment rates for COVID-19 vaccine administration in the "Additional Resources" section below. Certain settings use other payment methodologies, such as payment based on reasonable costs. Starting January 1, 2023, we'll also annually update the COVID-19 vaccine payment rates to reflect changes in costs related to administering preventive vaccines.

<sup>[3]</sup> Johnson & Johnson COVID-19 vaccine. On May 5, 2022, the FDA limited the authorized use of the Janssen COVID-19 vaccine. On June 1, 2023, [FDA revoked the EUA](#) for this vaccine.

<sup>[4]</sup> Administration booster codes should be billed for all applicable booster doses as approved and/or authorized by the FDA.

<sup>[5]</sup> On June 17, 2022, FDA authorized the 50MCG/0.5ML presentation of the Moderna COVID-19 vaccine to provide primary series doses in individuals 6 - 11 years of age in addition to the March 29, 2022, FDA authorization to provide booster vaccination doses in individuals 18 years and older.

<sup>[6]</sup> On October 12, 2022, the FDA authorized the Moderna bivalent product (dark blue cap with gray border) and its administration for use as a single booster dose in individuals 12 - 17 years old in addition to the August 31, 2022, FDA authorization as a single booster dose in individuals 18 years and older.